Neurogene (Neurogene) Other Gross PPE : $28.32 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Other Gross PPE?

Neurogene's Other Gross PPE for the quarter that ended in Mar. 2024 was $28.32 Mil.

Neurogene's quarterly Other Gross PPE declined from Sep. 2023 ($28.39 Mil) to Dec. 2023 ($28.34 Mil) and declined from Dec. 2023 ($28.34 Mil) to Mar. 2024 ($28.32 Mil).

Neurogene's annual Other Gross PPE increased from Dec. 2021 ($26.24 Mil) to Dec. 2022 ($28.69 Mil) but then declined from Dec. 2022 ($28.69 Mil) to Dec. 2023 ($28.34 Mil).

Neurogene Other Gross PPE Historical Data

The historical data trend for Neurogene's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Other Gross PPE Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Other Gross PPE

26.24

28.69

28.34

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial			-	28.52	28.39	28.34	28.32

Neurogene Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Neurogene (Neurogene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024